Genmab A/S announced its financial results for the second quarter of 2025, reporting a robust 19% increase in total revenue. This growth was primarily driven by a 27% surge in recurring revenue, bolstered by strong royalties from DARZALEX and Kesimpta, alongside accelerating contributions from EPKINLY and Tivdak.
The company's operating profit saw an impressive 56% growth in the first half of 2025, reaching $531 million in net profit. This profitability was achieved despite significant strategic investments, underscoring Genmab's disciplined approach to capital allocation.
Combined sales for EPKINLY and Tivdak soared by 60% year-over-year in the first half of 2025, contributing 31% to the company's total revenue growth. EPKINLY global sales reached $211 million, a 74% year-over-year increase, driven by accelerating adoption and new patient starts in the U.S.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.